Join
CohBar Inc. logo

CWBR

NASDAQ

CohBar Inc.

SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
$0.95+0.07 (+7.66%)
News25/Ratings1

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Latest news

25 items

CWBR FAQ

6 questions
  • What does CohBar Inc. do?
    CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which...
  • Where does CWBR stock trade?
    CohBar Inc. (CWBR) is listed on NASDAQ.
  • What sector and industry is CWBR in?
    CohBar Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.
  • What are analysts saying about CWBR?
    CohBar Inc. has had 1 recent analyst action on file. The most recent action was from WBB Securities: Buy with a $500.00 price target on 2021-08-11. Recent price targets cluster around $500.00.
  • What companies are similar to CWBR?
    Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare CWBR side-by-side with any of them on Quantisnow.
  • How can I track CWBR on Quantisnow?
    Quantisnow aggregates CohBar Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CWBR to receive live email and push alerts on every new disclosure.